Doravirine vs Etravirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Doravirine · Pifeltro
Marketed by Merck & Co.
NCT02275780 · Phase 3 · completed
This was a randomized, double-blind, active-controlled Phase 3 trial with 769 enrolled adults (385 doravirine, 384 darunavir/ritonavir). The primary endpoint was virologic suppression (HIV-1 RNA <50 copies/mL) at Week 48, a hard clinical endpoint. The non-inferiority comparison was met: the difference was 3.9 percentage points (95% CI -1.6 to 9.4), with the lower bound above the prespecified -10% margin. The trial therefore provides strong evidence that doravirine is non-inferior to darunavir/ritonavir.
Next expected readout: November 2026 · NCT04892654 (registry estimate)
Reported efficacy
Percentage of Participants With HIV-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48; Percentage of Participants With Tier-1 Neuropsychiatric Adverse Events (AEs) (Up to Week 48): Week 48 HIV-1 RNA <50 copies/mL: 84.3% doravirine/tenofovir/lamivudine vs 80.8% ATRIPLA; treatment difference 3.537 percentage points (95% CI -1.951 to 9.026), with a non-inferiority margin of -10. Tier-1 neuropsychiatric events: dizziness 8.8% vs 37.1% (difference -28.3, p<0.001); sleep disorders/disturbances 12.1% vs 25.5% (difference -13.5, p<0.001); altered sensorium 4.4% vs 8.2% (difference -3.8, p=0.033). (met)
Result source: NCT02403674
Etravirine · Intelence
Marketed by Johnson & Johnson
NCT00254046 · Phase 3 · completed
Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.
Reported efficacy
Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)
Result source: NCT00254046
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Doravirine | Etravirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | 83.8% vs 79.9%vs Daurunavir + RitonavirNCT022757803 other results
| 56% vs 39%a+17 vs placeboNCT00254046 |
| HIV-1 RNA 50 copies/mL or more (week 48) | 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778 | —Not posted · NCT00255099 |
| CD4 count, change (week 48) | 224.1 vs 206.7vs Daurunavir + RitonavirNCT0227578014 other results
| —Not posted · NCT00255099 |
HIV-1 RNA below 50 copies/mL (week 48)
- Doravirine
- 83.8% vs 79.9%vs Daurunavir + RitonavirNCT02275780
3 other results
- 84.3% vs 80.8% NCT02403674
- 73.1% vs 66% NCT02275780
- 77.5% vs 73.6% NCT02403674
- Etravirine
- 56% vs 39%a+17 vs placeboNCT00254046
HIV-1 RNA 50 copies/mL or more (week 48)
- Doravirine
- 0% vs 1.5%vs Baseline Antiretroviral Therapy (ART)NCT04223778
- Etravirine
- —Not posted · NCT00255099
CD4 count, change (week 48)
- Doravirine
- 224.1 vs 206.7vs Daurunavir + RitonavirNCT02275780
14 other results
- 192.7 vs 185.6 NCT02275780
- 217.1 vs 319.9 NCT04233879
- 182.4 vs 233.5 NCT04233879
- 0.5 vs 66.3 NCT04223791
- 5.4 vs 62.7 NCT04223791
- -19.7 vs 40.5 NCT04223791
- 239.6 vs 350.9 NCT04233879
- 259.2 vs 263.6 NCT01632345
- 191.9 vs 194.5 NCT01632345
- 133.6 vs 121.1 NCT01632345
- 152.3 vs 146 NCT01632345
- 140.7 vs 121.1 NCT01632345
- 112.9 vs 121.1 NCT01632345
- 154.1 vs 121.1 NCT01632345
- Etravirine
- —Not posted · NCT00255099
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
3 other shared endpoints and safety
Coverage. Doravirine: 7 of 7 rows · Etravirine: 7 of 7 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Doravirine Rows use multiple source trials | Etravirine Rows use multiple source trials |
|---|---|---|
| CD4+ absolute change · cells/uL No placebo or comparator arm | 42.5 cells/uL @ 96wka,b,c NCT03332095 · Phase 1/2 · combination | 224 cells/uL @ 96wk400 mg once dailya,b,c NCT00959894 · Phase 2 · registry result, not featured evidence 2 other source trials18.5 cells/uL @ 96wk NCT00128830 · Phase 2 · registry result, not featured evidence 120 cells/uL @ 96wk NCT00128830 · Phase 2 · registry result, not featured evidence |
| HIV-1 RNA absolute change · log No placebo or comparator arm | -2.1 log @ 48wka,b,c NCT03332095 · Phase 1/2 · combination | -1.53 log @ 48wka,b,c NCT00665847 · Phase 2 · registry result, not featured evidence |
| HIV-1 RNA Less Than 50 Copies responder rate · % of participants No placebo or comparator arm | 97.6% (n=42) @ 48wka,b NCT03332095 · Phase 1/2 · combination | 45.5% (n=22) @ 48wk400/100 mgd,a,b NCT00896051 · Phase 2 · registry result, not featured evidence · combination show 1 more dose50% (n=22) @ 48wk300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination |
| Dropout rate | 24.2%100 mge NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 19.6%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 10%Cohort 1: DOR NCT03332095 · Phase 1/2 2.2%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 20.4%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 8.2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 0% NCT04689737 · Phase 4 · registry result, not featured evidence 30.4%DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 80.2%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 17%Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence 42.9%DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 33.3%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 43.6%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 28.6% NCT04900974 · Phase 1 · registry result, not featured evidence 0% NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | n/a: no completion milestonef NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results20.3%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 36%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 40%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 24.8% NCT00665847 · Phase 2 · registry result, not featured evidence 20.3% NCT00903682 · Phase 2 · registry result, not featured evidence 34.1% NCT00128830 · Phase 2 · registry result, not featured evidence 5%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 16.7%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 17.9% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Discontinued due to AEs | 1.6%100 mge NCT02275780 · Phase 3 · combination show 44 more results—DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 —DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 3%MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 —Cohort 1: DOR NCT03332095 · Phase 1/2 —Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination —100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination — NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 —Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence —Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination —DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence —100 mg NCT01632345 · Phase 2 · registry result, not featured evidence —200 mg NCT01632345 · Phase 2 · registry result, not featured evidence —50 mg NCT01632345 · Phase 2 · registry result, not featured evidence —25 mg NCT01632345 · Phase 2 · registry result, not featured evidence — NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination —200 mg NCT01466985 · Phase 1 · registry result, not featured evidence —25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | 6.7%f NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results3.8%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 4%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 8%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 7.9% NCT00665847 · Phase 2 · registry result, not featured evidence 7.6% NCT00903682 · Phase 2 · registry result, not featured evidence 4.7% NCT00128830 · Phase 2 · registry result, not featured evidence —Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence —Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence —200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination —200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence — NCT01625169 · Phase na · registry result, not featured evidence · combination — NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Serious AEs | 11.7%100 mge NCT02275780 · Phase 3 · combination show 44 more results6.5%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 4.2%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 1.7%DOR/3TC/TDF Only (DOR/3TC/TDF From NCT02403674 · Phase 3 · HIV · phase 3 6%DOR/3TC/TDF Only (From Day 1) at B NCT02403674 · Phase 3 · HIV · phase 3 4.5%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 5.2%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 6.3%DOR/3TC/TDF Switch (Switch From EF NCT02403674 · Phase 3 · HIV · phase 3 8.2%DOR/3TC/TDF Switch at Week 96 Base NCT02403674 · Phase 3 · HIV · phase 3 —MK-1439A (DOR/3TC/TDF From Day 1) NCT02403674 · Phase 3 · HIV · phase 3 0%Cohort 1: DOR NCT03332095 · Phase 1/2 4.4%Cohort 2: DOR/3TC/TDF NCT03332095 · Phase 1/2 · combination 10.6%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 2%100 mg NCT04636437 · Phase 4 · registry result, not featured evidence · combination 25% NCT04689737 · Phase 4 · registry result, not featured evidence —DOR/ISL NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 4.3%DOR/ISL: Base Study Week 0 - Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 6.2%DOR/ISL: Base Study Week 48-Week 9 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 2.6%DOR/ISL: Base Study Week 96-Week 1 NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 0%DOR/ISL: Open-Label Extension Week NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 1.5%DOR/ISL: Post-Treatment Follow-Up NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 —100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 6.4%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 5.3%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.1%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 0%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 2.7%100 mg/0.75 mg NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 4.8%Group 1: DOR/ISL Weeks 0-48 NCT04223778 · Phase 3 · registry result, not featured evidence 4%Group 1: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —Group 1: Doravirine/Islatravir (DO NCT04223778 · Phase 3 · registry result, not featured evidence 3.7%Group 2: DOR/ISL Weeks 48-End of T NCT04223778 · Phase 3 · registry result, not featured evidence —DOR/ISL + ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL+ART NCT04233216 · Phase 3 · registry result, not featured evidence · combination 0%DOR/ISL: Treatment Naive Cohort NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Treatment Naive Cohort Ex NCT04295772 · Phase 2 · registry result, not featured evidence 2.7%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 0%DOR/ISL: Virologically Suppressed NCT04295772 · Phase 2 · registry result, not featured evidence 10.2%100 mg NCT01632345 · Phase 2 · registry result, not featured evidence 7.3%200 mg NCT01632345 · Phase 2 · registry result, not featured evidence 2.3%50 mg NCT01632345 · Phase 2 · registry result, not featured evidence 10%25 mg NCT01632345 · Phase 2 · registry result, not featured evidence 0% NCT04900974 · Phase 1 · registry result, not featured evidence — NCT02715700 · Phase 1 · registry result, not featured evidence · combination 0%200 mg NCT01466985 · Phase 1 · registry result, not featured evidence 0%25 mg NCT01466985 · Phase 1 · registry result, not featured evidence | 10%f NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results15.2%400 mg once daily NCT00959894 · Phase 2 · registry result, not featured evidence 8%400/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 16%300/100 mg NCT00896051 · Phase 2 · registry result, not featured evidence · combination 5% NCT00665847 · Phase 2 · registry result, not featured evidence 13.9% NCT00903682 · Phase 2 · registry result, not featured evidence 21.8% NCT00128830 · Phase 2 · registry result, not featured evidence 25%Cohort I: Treatment Experienced, 2 NCT01504841 · Phase 1/2 · registry result, not featured evidence 50%Cohort II: Treatment Experienced, NCT01504841 · Phase 1/2 · registry result, not featured evidence 0%200 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0%200 mg + 600/100 mg + 200 mg NCT04630002 · Phase 1 · registry result, not featured evidence · combination 0% NCT00871234 · Phase 1 · registry result, not featured evidence 0% NCT01625169 · Phase na · registry result, not featured evidence · combination 20% NCT01427504 · Phase na · registry result, not featured evidence · combination |
| Most frequent reported AEs | 100 mge diarrhoea 18.8% upper respiratory tract infection 16.7% headache 16.4% NCT02275780 · Phase 3 · combination show 33 more resultsnasopharyngitis 13.7% upper respiratory tract infection 7.2% headache 6.2% NCT02403674 · Phase 3 · HIV · phase 3 nasopharyngitis 9.7% upper respiratory tract infection 7.1% diarrhoea 6.3% NCT02403674 · Phase 3 · HIV · phase 3 aspartate aminotransferase increased 22.2% blood alkaline phosphatase increased 11.1% blood glucose increased 11.1% NCT03332095 · Phase 1/2 glomerular filtration rate decreased 55.6% alanine aminotransferase increased 46.7% blood creatinine increased 46.7% NCT03332095 · Phase 1/2 · combination 100 mg creatinine renal clearance decreased 10.6% low density lipoprotein increased 6.4% abdominal pain upper 2.1% NCT04636437 · Phase 4 · registry result, not featured evidence · combination 100 mg creatinine renal clearance decreased 8.2% aspartate aminotransferase increased 4.1% alanine aminotransferase increased 2% NCT04636437 · Phase 4 · registry result, not featured evidence · combination headache 8.1% covid-19 5.9% arthralgia 5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 13.1% lymphocyte count decreased 10.5% cd4 lymphocytes decreased 9.2% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 32.3% cd4 lymphocytes decreased 23.7% covid-19 12.4% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 lymphocyte count decreased 15.9% cd4 lymphocytes decreased 11.4% covid-19 1.5% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 covid-19 2.6% nasopharyngitis 2% diarrhoea 1% NCT04223791 · Phase 3 · registry result, not featured evidence · HIV · phase 3 100 mg/0.75 mg covid-19 14.1% headache 10.4% lymphocyte count decreased 9.1% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 24.1% cd4 lymphocytes decreased 10.5% covid-19 7.5% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 17.1% cd4 lymphocytes decreased 8.2% upper respiratory tract infection 2.7% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg lymphocyte count decreased 14.3% accidental overdose 0% arthralgia 0% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 100 mg/0.75 mg upper respiratory tract infection 6.3% insomnia 1.8% headache 0.9% NCT04233879 · Phase 3 · registry result, not featured evidence · combination · HIV · phase 3 headache 10.7% accidental overdose 7.1% covid-19 5.4% NCT04223778 · Phase 3 · registry result, not featured evidence lymphocyte count decreased 20.2% cd4 lymphocytes decreased 14% covid-19 13% NCT04223778 · Phase 3 · registry result, not featured evidence covid-19 17.5% lymphocyte count decreased 13.5% cd4 lymphocytes decreased 12% NCT04223778 · Phase 3 · registry result, not featured evidence blood creatine phosphokinase increased 28.6% (placebo 14.3%) diarrhoea 28.6% (placebo 14.3%) anaemia 14.3% (placebo 0%) NCT04233216 · Phase 3 · registry result, not featured evidence · combination dizziness 33.3% dyspepsia 33.3% headache 33.3% NCT04295772 · Phase 2 · registry result, not featured evidence covid-19 100% adjustment disorder 0% back pain 0% NCT04295772 · Phase 2 · registry result, not featured evidence oropharyngeal pain 10.8% cough 8.1% nasal congestion 8.1% NCT04295772 · Phase 2 · registry result, not featured evidence cough 28.6% oropharyngeal pain 21.4% rhinorrhoea 21.4% NCT04295772 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 17.6% diarrhea 14.8% dizziness 14.8% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 29.3% nausea 22% headache 17.1% NCT01632345 · Phase 2 · registry result, not featured evidence 50 mg abnormal dreams 20.9% nausea 16.3% headache 14% NCT01632345 · Phase 2 · registry result, not featured evidence 25 mg diarrhea 25% fatigue 17.5% influenza 15% NCT01632345 · Phase 2 · registry result, not featured evidence 200 mg diarrhoea 33.3% (placebo 0%) headache 33.3% (placebo 33.3%) abdominal pain 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence 25 mg alanine aminotransferase increased 16.7% (placebo 0%) aspartate aminotransferase increased 16.7% (placebo 0%) decreased appetite 16.7% (placebo 0%) NCT01466985 · Phase 1 · registry result, not featured evidence | f cough 2.8% upper respiratory tract infection 2.8% pregnancy 2.2% NCT00980538 · Phase 3 · registry result, not featured evidence show 13 more results400 mg once daily elevated level of transaminase 11.4% hyperbilirubinemia 7.6% hyperlipidemia 7.6% NCT00959894 · Phase 2 · registry result, not featured evidence 400/100 mg cough 16% headache 12% influenza 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination 300/100 mg cough 20% nausea 16% blood bilirubin increased 12% NCT00896051 · Phase 2 · registry result, not featured evidence · combination upper respiratory tract infection 26.7% diarrhoea 15.8% cough 12.9% NCT00665847 · Phase 2 · registry result, not featured evidence nasopharyngitis 21.5% headache 16.5% diarrhoea 10.1% NCT00903682 · Phase 2 · registry result, not featured evidence diarrhoea 17.5% upper respiratory tract infection 17.1% sinusitis 11.4% NCT00128830 · Phase 2 · registry result, not featured evidence blood bicarbonate decreased 90% blood sodium decreased 70% nasal congestion 70% NCT01504841 · Phase 1/2 · registry result, not featured evidence cough 100% nasal congestion 100% rhinorrhoea 100% NCT01504841 · Phase 1/2 · registry result, not featured evidence 200 mg + 200 mg headache 18.8% toothache 12.5% diarrhoea 6.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination 200 mg + 600/100 mg + 200 mg rash maculo-papular 20% scleral hyperaemia 20% headache 13.3% NCT04630002 · Phase 1 · registry result, not featured evidence · combination headache 14.3% constipation 10.7% diarrhea 7.1% NCT00871234 · Phase 1 · registry result, not featured evidence breast tenderness 66.7% diarrhea 11.1% headache 11.1% NCT01625169 · Phase na · registry result, not featured evidence · combination altered taste 64% headache 16% rash 16% NCT01427504 · Phase na · registry result, not featured evidence · combination |
Notes
- aTrial phases differ: Phase 1/2 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- ePopulation comparability has not been reviewed for 24 of these studies.
- fPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Doravirine
show 14 more results
show 3 more results
show 3 more results
+ 39 further endpoints in the CSV export.
Etravirine
show 2 more results
show 2 more results
show 7 more results
show 1 more result
show 7 more results
show 1 more result
show 1 more result
show 1 more result
show 5 more results
show 1 more result
+ 5 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Doravirine's landscape · Etravirine's landscape